Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as
monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients with type
2 Diabetes for 52 weeks administration.